The glycosyltransferase ST3GAL4 drives immune evasion in acute myeloid leukemia by synthesizing ligands for the glyco-immune checkpoint receptor Siglec-9
Leukemia · 2025-02 · 39 (2) · 346-359
DOI: 10.1038/s41375-024-02454-w ↗Kurz gefasst
Fachartikel in der Zeitschrift Leukemia, online erschienen am 17.11.2024. Verfasst von Vignesh Krishnamoorthy und 10 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, BC, Canada. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, Sialyltransferases, Sialic Acid Binding Immunoglobulin-like Lectins, Immune Evasion. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIGMS NIH HHS, Cancer Research Society, Canadian Cancer Society Research Institute.
Abstract (Originalsprache)
Immunotherapy has demonstrated promise as a treatment for acute myeloid leukemia (AML). However, there is still an urgent need to identify new molecules that inhibit the immune response to AML. Most prior research in this area has focused on protein-protein interaction interfaces. While carbohydrates also regulate immune recognition, the role of cell-surface glycans in driving AML immune evasion is comparatively understudied. The Siglecs, for example, are an important family of inhibitory, glycan-binding signaling receptors that have emerged as prime targets for cancer immunotherapy in recent years. In this study, we find that AML cells express ligands for the receptor Siglec-9 at high levels. Integrated CRISPR genomic screening and clinical bioinformatic analysis identified ST3GAL4 as a potential driver of Siglec-9 ligand expression in AML. Depletion of ST3GAL4 by CRISPR-Cas9 knockout (KO) dramatically reduced the expression of Siglec-9 ligands in AML cells. Mass spectrometry analysis of cell-surface glycosylation in ST3GAL4 KO cells revealed that Siglec-9 primarily binds N-linked sialoglycans on these cell types. Finally, we found that ST3GAL4 KO enhanced the sensitivity of AML cells to phagocytosis by Siglec-9-expressing macrophages. This work reveals a novel axis of immune evasion and implicates ST3GAL4 as a possible target for immunotherapy in AML.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, BC, Canada.
- Terry Fox Laboratory, British Columbia Cancer Research Institute, Vancouver, BC, Canada.
- Complex Carbohydrate Research Center, University of Georgia, Athens, GA, USA.
- Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, BC, Canada. simon.wisnovsky@ubc.ca.
ORCID-Profile: Jimmy Kim, Lidia Piatnitca, Bhoj Kumar, Mehrnoush Taherzadeh Ghahfarrokhi, Simon Wisnovsky
Förderung
- NIGMS NIH HHS
- Cancer Research Society
- Canadian Cancer Society Research Institute
- Gouvernement du Canada | Canadian Institutes of Health Research
Zitieren
APA
Krishnamoorthy, V., Daly, J., Kim, J., Piatnitca, L., Yuen, K. A., Kumar, B., Taherzadeh Ghahfarrokhi, M., Bui, T. Q. T., Azadi, P., Vu, L. P., & Wisnovsky, S. (2025). The glycosyltransferase ST3GAL4 drives immune evasion in acute myeloid leukemia by synthesizing ligands for the glyco-immune checkpoint receptor Siglec-9. Leukemia, 39(2), 346-359. https://doi.org/10.1038/s41375-024-02454-w
Vancouver
Krishnamoorthy V, Daly J, Kim J, Piatnitca L, Yuen KA, Kumar B, et al. The glycosyltransferase ST3GAL4 drives immune evasion in acute myeloid leukemia by synthesizing ligands for the glyco-immune checkpoint receptor Siglec-9. Leukemia. 2025;39(2):346-359. doi:10.1038/s41375-024-02454-w
BibTeX
@article{Krishnamoorthy2025,
author = {Krishnamoorthy, Vignesh and Daly, John and Kim, Jimmy and Piatnitca, Lidia and Yuen, Katie A and Kumar, Bhoj and Taherzadeh Ghahfarrokhi, Mehrnoush and Bui, Tom Q T and Azadi, Parastoo and Vu, Ly P and Wisnovsky, Simon},
title = {The glycosyltransferase ST3GAL4 drives immune evasion in acute myeloid leukemia by synthesizing ligands for the glyco-immune checkpoint receptor Siglec-9},
journal = {Leukemia},
year = {2025},
volume = {39},
number = {2},
pages = {346--359},
doi = {10.1038/s41375-024-02454-w}
}
EUVIMED